Mirikizumab Shows Promise for Moderate to Severe Crohn’s
WASHINGTON, DC — The selective interleukin (IL)–23p29 monoclonal antibody mirikizumab demonstrated safety and efficacy in people with moderate to severe ...
Read moreWASHINGTON, DC — The selective interleukin (IL)–23p29 monoclonal antibody mirikizumab demonstrated safety and efficacy in people with moderate to severe ...
Read more© 2023 earth-news.info
. . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . %%%. . . * . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ - - - - - - - - - - - - - - - - - - - - . . . . .